|
Dec 2
|
Insider Sell: EVP Joseph Laplume Sells Shares of Charles River Laboratories International Inc (CRL)
|
|
Nov 29
|
Charles River (CRL) Backs the Quest to Cure SPG56 via New Deal
|
|
Nov 28
|
Charles River and Genetic Cures for Kids Announce Gene Therapy Manufacturing Collaboration
|
|
Nov 27
|
Charles River Laboratories to Present at Evercore ISI Investor Conference
|
|
Nov 17
|
Charles River (CRL) Widens CliniPrime GMP Suite With New Launch
|
|
Nov 17
|
Charles River Laboratories International Insiders Added US$1.91m Of Stock To Their Holdings
|
|
Nov 17
|
Chairman of Charles River Laboratories International James Foster Buys 2.3% More Shares
|
|
Nov 16
|
Charles River Introduces CliniPrime Cryopreserved Leukopaks, Expanding Suite of GMP-Compliant Cellular Products
|
|
Nov 13
|
Charles River and Aitia Enter Strategic Agreement to Utilize Logica in Discovery Programs for Neurodegenerative Diseases and Oncology
|
|
Nov 10
|
Charles River Laboratories International, Inc. (NYSE:CRL) Q3 2023 Earnings Call Transcript
|
|
Nov 9
|
Charles River Laboratories’ Industry Experts to Present Advanced Modalities at Neuroscience 2023
|
|
Nov 9
|
Q3 2023 Charles River Laboratories International Inc Earnings Call
|
|
Nov 8
|
Charles River Laboratories Posts Mixed Q3 Results; Updates 2023 Outlook
|
|
Nov 8
|
Charles River's (CRL) Q3 Earnings Beat, Margins Decline
|
|
Nov 8
|
Charles River (CRL) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
|
|
Nov 8
|
Charles River Laboratories Announces Third-Quarter 2023 Results
|
|
Nov 6
|
Unlocking Q3 Potential of Charles River (CRL): Exploring Wall Street Estimates for Key Metrics
|
|
Sep 12
|
Long-Term Returns of Billionaire Barry Rosenstein’s Activist Targets
|
|
Sep 11
|
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
|
|
Sep 8
|
Charles River (CRL) Down 6.1% Since Last Earnings Report: Can It Rebound?
|